Cowen & Co. analyst Marc Frahm maintained a Buy rating on Blueprint Medicines (BPMC) today. The company’s shares opened today at $76.42.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 4.7% and a 63.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Odonate Therapeutics Llc, Magenta Therapeutics Inc, and Unum Therapeutics Inc.
The the analyst consensus on Blueprint Medicines is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $109 and a one-year low of $44.58. Currently, Blueprint Medicines has an average volume of 327.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.
